What tests are used to detect lacosamide-related arrhythmias?
Lacosamide can affect cardiac electrical conduction, most notably by prolonging PR interval and, in some cases, contributing to arrhythmias. Clinicians detect possible lacosamide-induced arrhythmia or conduction effects using these tests:
- Electrocardiogram (ECG). A standard 12-lead ECG can show conduction changes such as PR-interval prolongation and rhythm disturbances. [1]
- Continuous cardiac monitoring (telemetry) in higher-risk situations. If symptoms occur (e.g., palpitations, syncope) or the patient is hospitalized, continuous monitoring can detect intermittent arrhythmias that a single ECG might miss. [1]
When do doctors order ECG vs longer monitoring?
In practice, the choice depends on symptoms and risk:
- If there are symptoms like palpitations, dizziness, or fainting, clinicians often start with an ECG and then consider continuous monitoring if events are intermittent. [1]
- If a patient is identified as higher risk (for example, due to existing conduction disease or concomitant medications that affect cardiac conduction), clinicians may use ECG monitoring strategies more proactively. [1]
What findings on ECG point to lacosamide-related conduction problems?
The key ECG signals clinicians look for include:
- PR-interval prolongation (slowed AV nodal conduction). [1]
- Other rhythm or conduction abnormalities that may emerge with toxicity or predisposition to conduction disturbances, which continuous monitoring can catch if they are not present on a single tracing. [1]
Does blood testing help detect lacosamide-induced arrhythmia?
Blood tests are not direct “arrhythmia detectors,” but they can support the workup by looking for contributing factors that increase arrhythmia risk (for example, electrolyte disturbances). The primary tools for detecting the arrhythmia itself remain ECG-based testing and cardiac rhythm monitoring. [1]
Are there recommended baseline checks before starting lacosamide?
A baseline ECG can help identify pre-existing conduction abnormalities, and clinicians may repeat ECGs after dose changes or if symptoms develop, depending on the patient’s risk. [1]
Sources
- DrugBank – Lacosamide (Cardiovascular/ECG considerations and monitoring information): https://go.drugbank.com/drugs/DB06643